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Introduction: Fibroblast-like synoviocytes (FLS) play an important role in the pathogenesis of rheumatoid arthritis
(RA). This study aimed to investigate the role of glucose 6-phosphate isomerase (GPI) in the proliferation of RA-FLS.
Methods: The distribution of GPI in synovial tissues from RA and osteoarthritis (OA) patients was examined by
immunohistochemical analysis. FLS were isolated and cultured, cellular GPI level was detected by real-time polymerase
chain reaction (PCR) and Western blot analysis, and secreted GPI was detected by Western blot and enzyme-linked
immunosorbent assay (ELISA). Doxorubicin (Adriamycin, ADR) was used to induce apoptosis. Cell proliferation was
determined by MTS assay. Flow cytometry was used to detect cell cycle and apoptosis. Secreted pro-inflammatory
cytokines were measured by ELISA.
Results: GPI was abundant in RA-FLS and was an autocrine factor of FLS. The proliferation of both RA and OA FLS was
increased after GPI overexpression, but was decreased after GPI knockdown. Meanwhile, exogenous GPI stimulated,
while GPI antibody inhibited, FLS proliferation. GPI positively regulated its receptor glycoprotein 78 and promoted G1/S
phase transition via extracellular regulated protein kinases activation and Cyclin D1 upregulation. GPI inhibited
ADR-induced apoptosis accompanied by decreased Fas and increased Survivin in RA FLS. Furthermore, GPI increased
the secretion of tumor necrosis factor-α and interleukin-1β by FLS.
Conclusions: GPI plays a pathophysiologic role in RA by stimulating the proliferation, inhibiting the apoptosis, and
increasing pro-inflammatory cytokine secretion of FLS.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
joint disease that eventually leads to the destruction of
the joint architecture. Synovial hyperplasia is considered
a hallmark of RA, in which fibroblast-like synoviocytes
(FLS) and immune cells communicate in a unique in-
flammatory microenvironment. The hyperplasia of the
synovial lining is largely composed of increased numbers
of FLS and macrophages. Other inflammatory cells, such
as mast cells, dendritic cells, macrophages, and lympho-
cytes, are also recruited and accumulate in the sub lin-
ing. As they accumulate to form pannus tissue, RA-FLS
exhibit local tumor-like destructive and invasive charac-
teristics. Moreover, FLS contribute to the inflammatory* Correspondence: flieying@yeah.net
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stated.microenvironment through directly producing pro-
inflammatory factors or indirectly activating or recruit-
ing other immune cells [1,2]. Therefore, FLS play a
critical role in RA pathogenesis, and targeting FLS might
improve clinical outcomes of inflammatory arthritis
without suppressing systemic immunity [3].
Glucose-6-phosphate isomerase (GPI; EC 5.3.1.9), also
known as phosphoglucose isomerase and phosphohexose
isomerase, catalyzes the interconversion of D-glucose-6-
phosphate and D-fructose-6-phosphate, a crucial step in
glycolysis and gluconeogenesis [4]. In addition to its en-
zymatic activity, GPI acts as a cytokine and growth factor
in a wide variety of extracellular processes [5-8]. GPI has
been identified as a motility factor: autocrine motility fac-
tor (AMF) [5], neuroleukin [7,8] or maturation factors [9].
AMF/GPI is a multifunctional cytokine that exhibits multi-
functional growth factor-like activity via a unique cognate
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AMFR) [10]. Many studies have shown that AMF not only
stimulates AMF-producing tumor cell motility in an auto-
crine manner, but also acts as a paracrine factor for vein
endothelial cells. AMF induces angiogenesis by stimulating
cell motility and up-regulating vascular endothelial growth
factor receptor (VEGFR) expression [11]. Overexpression
of AMF/GPI and AMFR has been found in a wide
spectrum of malignancies, and is associated with cancer
progression, metastasis and angiogenesis [12-16].
The autoantibodies against glucose-6-phosphate isom-
erase (anti-GPI Abs) were present in the K/BxN T-cell
receptor (TCR)-transgenic inflammatory arthritis mouse
model [17]. Furthermore, recombinant human GPI was
shown to have the ability to induce chronic arthritis in
the mice, which was major histocompatibility complex
(MHC) associated and B-cell dependent [18]. The total
GPI protein level, in both enzymatically active and in-
active forms, was significantly higher in the sera of RA
patients compared with patients with other immune-based
or non-immune-based inflammatory arthritis [19]. We pre-
viously demonstrated that 76.1% of patients with RA, but
not controls, had increased concentration of soluble GPI in
their sera and synovial fluid (SF), and serum GPI concen-
tration was higher in active RA patients than in non-active
RA patients [20]. However, it remains unclear where exces-
sive GPI comes from in RA joints, and whether it is associ-
ated with joint tissue pathological changes of RA. In this
study, we aimed to characterize the features of autocrine
GPI from RA-FLS, and clarify the role of GPI in the regula-
tion of FLS proliferation and apoptosis.
Methods
Patients and controls
Synovial tissues were obtained from eight RA patients
and eight osteoarthritis (OA) patients who underwent
knee arthroscopic or replacement surgery at Shanghai
East Hospital. Serum samples were taken before the sur-
gery from all 16 patients. All the subjects fulfilled the
2010 American College of Rheumatology (ACR) criteria
for the diagnosis of RA and OA [21]. Informed consent
was obtained from all patients and the study protocol
was approved by the Ethics Committee of Shanghai East
Hospital (2012-df-043). There were no differences in eth-
nicity among the groups and no patient with RA or OA
had tumor and renal disease. RA patients were divided
into two groups according to serum GPI level: GPI (+) RA
and GPI (−) RA, with 0.2 mg/L as the cut-off value.
Isolation and culture of fibroblast-like synoviocytes
Synovial tissues were minced into pieces of 2 to 3 mm
in size and spread on the bottom of cell culture flasks in
RPMI 1640 medium (Life Technologies, Carlsbad, CA,
USA) at 37°C for 6 hours. Next, the tissues wereincubated with complete RPMI 1640 medium supple-
mented with 10% fetal calf serum in a humidified atmos-
phere containing 5% CO2. The medium was changed every
three to five days and non-adherent tissue pieces were
carefully removed. FLS were grown further over four to six
passages. To characterize the cytological phenotype of syn-
ovial cultures, the third passage cells were stained with
mouse monoclonal antibodies (mAb) to human fluorescein
isothiocyanate (FITC)-CD14 and phycoerythrin (PE)-CD90
(eBioscience, San Diego, CA, USA), and showed 2.8%
CD14 and 97.0% CD90 expression, as measured by flow
cytometry. For cell treatment, FLS were treated with hu-
man GPI (Abcam product number: ab87625, endotoxin:
<1 EU/μg protein, Cambridge, UK).
RNA interference and plasmid construction
To design specific small interfering RNA (siRNA) targeting
GPI and gp78 (named siGPI and sigp78), several sequences
from the human GPI gene were selected using BLOCK-iT™
RNAi Designer (Life Technologies, Carlsbad, CA, USA).
The target sequences for GPI siRNA (siGPI: 5′-CCATACG
GAAGGGTCTGCATCACAATT-3′), gp78 siRNA (sigp78:
5′-GTCG GCACAAGAACTATCTTT-3′) and negative
control siRNA (si-NC: 5′-TTCTCCGAA-CGTGTCAC
GT-3′) were synthesized by Genepharma Inc (Shanghai,
China). SiRNA transfection was performed using Lipofec-
tamine® 2000 (Invitrogen, Carlsbad, CA, USA). According
to the sequence of GPI cDNA (NM_001184722.1), we de-
signed the primers 5′-CGGAATTCCA TGGTAGCTCTC
TGCAGCCT-3′ (forward) and 5′-CCCTCGAGGTTAT
TGGACTCTGG CCTCG C-3′ (reverse), and obtained
the full length of GPI cDNA by PCR. GPI cDNA was
inserted into pcDNA3.1-Flag (Invitrogen) vector and plas-
mid DNA transfection was performed using Lipofecta-
mine -LTX (Invitrogen). PCI-Neo-gp78/JM20 (plasmid
13303) was purchased from Addgen (Teddington, UK).
Immunohistochemical analysis
The tissues were fixed in 10% neutral buffered formalin
and embedded in paraffin. Next, the tissues were cut
into 5-μm thick sections, deparaffinized and rehydrated.
The sections were then subjected to hematoxylin and
eosin (H&E) or immunohistochemical staining. For immu-
nostaining, the sections were heated at 95°C for 20 minutes
with Dako Target Retrieval Solution (Dako, Copenhagen,
Denmark). Sections were incubated with mouse anti-GPI
mAb (1:500, Abcam Cambridge, UK) or mouse anti-gp78
mAb (1:100, Santa-Cruz Dallas, TX, USA) at 4°C overnight,
and then incubated with second antibody (Envision™
Detection Kit, Dako) for 30 minutes at room temperature.
Finally, the sections were visualized by using diaminoben-
zidine (DAB) substrate kit (Dako), according to the manu-
facturer’s instructions. Mouse serum was used instead of
primary antibody as a negative control.
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the CellTiter 96® Aqueous One Solution Cell Prolifera-
tion Assay kit (Promega, Beijing, China), according to
the manufacturer’s instructions. Briefly, cells were plated
at 1 × 103 cells/well in 96-well plates and cultured for
different periods. At the end of each period, 20 μl MTS
was added to each well and then incubated at 37°C for
4 hours. Plates were read at 490 nm on a spectrophoto-
metric plate reader (Bio-Rad, Hercules, CA, USA) with a
reference wavelength at 650 nm. The index for stimulating
cell proliferation was calculated as intervention group
optical density (OD) value/blank control group OD value.
Flow cytometry analysis of apoptosis and cell cycle
FLS were trypsinized and collected for the detection of
apoptosis by using Annexin V-FITC Apoptosis Detec-
tion Kit (eBioscience). Briefly, FLS were washed twice
with cold PBS and resuspended in 500 μl binding buffer
(10 mM HEPES-NaOH, pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2) at a concentration of 1 × 106 cells/ml. After the
addition of 5 μl Annexin V-FITC solution and Propi-
dium solution (PI, 2.5 μg/ml, Sigma-Aldrich, St. Louis,
MO, USA), the cells were incubated for 15 minutes at
room temperature and then analyzed by flow cytometer
(Beckman Coulter, Fullerton, CA, USA). Moreover, cells
in the logarithmic growth phase were prepared as a single
cell suspension at 1 × 106 cells/ml, fixed with ethanol
and then cryopreserved. FLS were resuspended in
500 μl pre-cold PBS and incubated at 37°C for 30 mi-
nutes after the addition of RNase A solution. After the
addition of 20 μl PI (50 μg/ml), the percentages of G1
phase, S phase and G2 phase cells were determined by
flow cytometry. The index for apoptosis was calculated
as the number of cells undergoing apoptosis/the num-
ber of total cells.
Quantitative real-time polymerase chain reaction
Total RNA was extracted from FLS using TRIzol™ (Invi-
trogen), and reverse transcription was performed using
first strand cDNA synthesis kit (TaKaRa, Dalian, China),
according to the manufacturer’s instructions. Real-time
PCR was performed using Premix Ex Taq SYBR Green
PCR (TaKaRa), according to the manufacturer’s instruc-
tions, on an ABI PRISM 7300 (Applied Biosystems, Foster
City, CA, USA). The sequences of the primers were as
follows: GPI 5′-AGGCTGCTGCCACATA-AGGT-3′,
5′-AGCGTCGTGAGAGGTCACTTG-3′; gp78 5′-CCAT
CATCAG CGCCTAC CG-3′, 5′-AACCAGAGGCACCA
CATGAC-3′; Fas 5′-CCCACCTACGTA CTGGCCTA-3′,
5′ -CTTGGCCTTGGGTGTGTACT-3′; Bcl-2 5′-AGTTC
GGTGG-GGTCATGTGTG-3′, 5′-CTTCAGAGACAGCC
AGGAGAAATC-3′; Bax 5′-TTCTGACGGCAACTTCAA
CTG-3′, 5′-TGAGGAGGCTTGAGGAGTCTC- 3′; Survivin
5′- TGCCTGGCAGCCC TTTCTCA-3′, 5′-TGGCACGGCGCACTTTCTTC-3′; Caspase-3 5′-TGGAACAAAT
GG ACCTGTTGA-3′, 5′-TAATAACCAGGTGCTGTGG
AGT-3′ and GAPDH 5′-TGACTT CAACAGCGACA
CCCA 3′, 5′ -CACCCTGTTGCTGTAG CCAAA −3′.
GAPDH was used as the internal control.Western blot analysis
Approximately 2 × 106 cells were lysed in lysis buffer and
the lysates were centrifuged at 14,000 rpm for 15 minutes.
The protein concentration in the supernatant was deter-
mined using the Bradford method (Bio-Rad). Protein
samples were separated on 12% SDS-PAGE and then
transferred onto nitrocellulose membranes (Amersham
Pharmacia Biotech, Uppsala, Sweden). The membranes
were incubated with antibody for GPI (Abcam), gp78
(Santa-Cruz), P-ERK1/2, ERK1/2, Cyclin D1 (Cell
Signaling Technology, Danvers, MA, USA), Bax, Bcl2,
Fas, Survivin, Cleaved-Caspase-3 or Caspase-3 (Abcam),
then incubated with horseradish peroxidase-conjugated
secondary antibody. All immunoreactive proteins were
visualized with SuperSignals west Pico Chemilumines-
cent Substrate (Thermo Fisher Scientific, Rockford, IL,
USA).Co-immunoprecipitation analysis
FLS were transfected with pcDNA3.1-GPI- Flag. The
cell lysates were collected 48 hours later for co-
immunoprecipitation (Co-IP) assay by using FLAG® Im-
munoprecipitation Kit (Sigma-Aldrich) according to the
manufacturer’s instructions. The bound fragments were
analyzed by Western blot analysis.Enzyme-linked immunosorbent assay
Human TNF-α, IL-1β, TGF-β and IL-6 levels were mea-
sured in the supernatant of FLS by using commercially
available kits (R&D Systems China, Shanghai, China), ac-
cording to the manufacturer’s instructions. Serum G6PI
level was measured by using GPI enzyme-linked im-
munosorbent assay (ELISA) Kit (Beijia Biochemical,
Shanghai, China). The biological reference interval of
serum G6PI level was set to ≤0.2 mg/L, in accordance with
the manufacturer’s instructions.Statistical analysis
For paired samples, Wilcoxon’s matched pairs signed rank
test was used. For multiple related samples, the Friedman
M test was used. Further pairwise comparisons were ana-
lyzed using a multiple related samples q test if appropriate.
SPSS19.0 program package (SPSS Inc., Chicago, IL, USA)
was used for all statistical analyses. A P value of less than
0.05 was considered statistically significant.
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Glucose 6-phosphate isomerase is abundant in
fibroblast-like synoviocytes of glucose 6-phosphate
isomerase (+) rheumatoid arthritis patients
To compare the distribution of GPI and its receptor
gp78 in synovial tissues from RA and OA patients, we
performed immunohistochemical analysis and found that
both GPI and gp78 were detected in the synoviocytes of
RA and OA. GPI immunostaining was mainly localized in
the cytoplasm and/or interstitial cell space and immuno-
positive cells had a diffuse distribution, while gp78 was
mainly localized in the cytoplasm and was weak in the
stroma (Figure 1A).
Furthermore, we detected the expression of GPI in
FLS by Western blot and quantitative RT-PCR analysis.
The results showed that GPI was present in FLS of
both RA and OA. In addition, GPI level was higher inFigure 1 GPI is highly expressed and secreted in RA-FLS. A, Immunohistoc
and OA patients (OA serum GPI: 0.1 μg/ml; RA serum GPI: 1.8 μg/ml). Origi
analysis (bottom) of GPI level in FLS. OA (n = 8, serum GPI concentration <0
μg/ml), GPI (−) RA (n = 4, serum GPI concentration <0.2 μg/ml). Friedman’s
blot (top) and ELISA (bottom) analysis of GPI level in the supernatant of FL
D, Western blot (top) and quantitative RT-PCR analysis (bottom) of the leve
plasmids and siRNAs. Data were shown as mean ± SD. P values were determ
R = number of replicates; GPI, glucose 6-phosphate isomerase; gp78, glycop
synoviocytes; NC, negative control).RA-FLS than in OA-FLS, and GPI level was increased
in GPI (+) RA patients compared to GPI (−) RA
patients (Figure 1B). These results demonstrate that
GPI is abundant in RA-FLS, especially in GPI (+) RA
patients.
Glucose 6-phosphate isomerase is an autocrine factor of
fibroblast-like synoviocytes
To test autocrine GPI/AMF in FLS, we detected secreted
GPI in the culture supernatant of FLS by Western blot
analysis (Figure 1C). Next, we transfected GPI siRNA
and overexpression plasmid to RA-FLS, respectively.
The results showed that the secreted GPI level was di-
minished in GPI knockdown FLS but was significantly
increased in GPI overexpressing FLS, compared to con-
trol (Figure 1D). These results suggest that GPI is an
autocrine factor of FLS.hemistry staining of GPI and GP78 in arthritic synovial tissues from RA
nal magnification × 200. B, Western blot (top) and quantitative RT-PCR
.2 μg/ml), GPI (+) RA (n = 4, serum GPI concentration = 1.3 ± 0.8
M test and SNK-q test were used for statistical analysis. C, Western
S. Friedman’s M test and SNK-q test were used for statistical analysis.
ls of secreted and cellular GPI in FLS transfected with expression
ined by Wilcoxon signed-rank test. (N = number of individuals,
rotein 78;RA, rheumatoid arthritis; OA, osteoarthritis; FLS, fibroblast-like
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To evaluate the pathological significance of GPI accumu-
lation for RA progression, we modulated GPI and gp78
expression levels in RA-FLS by the transfection of the cells
with GPI and gp78 siRNA duplexes or expression plas-
mids. As expected, the transfection of GPI and gp78
siRNA markedly reduced the protein levels of GPI and
gp78, while the transfection of GPI and gp78 expression
vector enhanced GPI and gp78 protein levels (Figure 2A).
MTS assay showed that GPI overexpression dramatically
increased the proliferation of both RA and OA FLS,
whereas GPI knockdown reduced the proliferation of FLS.
gp78 knockdown also reduced the proliferation of FLS,
but gp78 overexpression had no significant effect on the
proliferation of FLS compared to the control (Figure 2B).
To confirm these results, next we cultured RA-FLS
and OA-FLS in growth medium in the presence of GPI
or GPI antibody. GPI stimulated OA-FLS proliferation
in a non-concentration-dependent manner, but promoted
RA-FLS proliferation in a concentration-dependent man-
ner (Figure 2C). On the contrary, GPI antibody showed
inhibitory effects on the proliferation of RA-FLS and OA-
FLS in a concentration-dependent manner (Figure 2D).
Collectively, these results suggest that GPI promotes the
proliferation of FLS.
Glucose 6-phosphate isomerase regulates cell cycle of
fibroblast-like synoviocytes
Next, we examined the effects of GPI on the cell cycle of
FLS. Flow cytometry analysis showed that the number of
FLS was markedly lower in the G1 phrase, but was in-
creased in the S phrase after transfection with GPI expres-
sion vector. On the contrary, GPI knockdown caused a
stagnation of G1-S transition of FLS (Figure 3A). To inves-
tigate the mechanism by which GPI regulates the cell cycle
of FLS, we found that knockdown of endogenous GPI led
to the downregulation of its receptor gp78 (Figure 3B).
Co-IP analysis showed a direct interaction between GPI
and GP78 (Figure 3C). Moreover, we detected the levels of
cell cycle regulatory proteins. Compared with the control
group, the levels of P-ERK1/2 and Cyclin D1 were in-
creased after GPI overexpression, while ERK1/2 level was
not significantly changed (Figure 3D). These data indi-
cated that GPI positively regulates its receptor gp78 and
promotes G1/S phase transition via the activation of ERK
and the upregulation of Cyclin D1 expression.
Glucose 6-phosphate isomerase inhibits
doxorubicin-induced apoptosis in rheumatoid
arthritis-fibroblast-like synoviocytes
Doxorubicin (Adriamycin, ADR) is a well-known apoptosis-
inducing agent. To examine the effect of GPI on the apop-
tosis of FLS, we used ADR to treat RA-FLS. Flow cytometryanalysis showed that GPI knockdown led to the apoptosis in
FLS isolated from RA or OA, even without ADR treatment.
When FLS were treated with ADR, the apoptosis ratios
were increased in GPI knockdown and control cells, with-
out significant difference between them. In contrast, GPI
overexpression diminished the apoptosis of FLS treated
with ADR (Figure 4A).
To further confirm the role of GPI in the apoptosis of
FLS, we treated FLS from RA and OA patients with ex-
ogenous GPI, and detected the apoptosis of FLS by
Annexin V-FITC/PI assay. We observed that GPI sig-
nificantly decreased ADR-induced apoptosis of FLS
isolated from RA (GPI at 1 μg/ml, P <0.05; GPI at
10 μg/ml, P <0.01). GPI also attenuated the apoptosis
of FLS isolated from OA (GPI at 10 μg/ml, P <0.05)
(Figure 4B). When we treated FLS from RA and OA
patients with GPI antibody, GPI antibody consistently
led to increased apoptosis of RA-FLS and OA-FLS in a
concentration-dependent manner (Figure 4C).
To elucidate the molecular mechanism underlying
GPI-attenuated apoptosis of FLS, we detected the ex-
pression of apoptosis-related proteins in RA-FLS. RT-
PCR analysis showed that GPI overexpression led to a
decreased Fas mRNA level and increased Survivin
mRNA level, while GPI knockdown led to an increased
Fas mRNA level and decreased Survivin mRNA level.
Western blot analysis consistently showed that GPI
overexpression led to decreased protein levels of Fas and
Cleaved Caspase-3 and an increased Survivin protein
level, while GPI knockdown led to increased protein
levels of Fas and Cleaved Caspase-3 and a decreased
Survivin protein level (Figure 4A).
Furthermore, we treated RA-FLS with GPI in the ab-
sence or presence of ADR. We observed that GPI signifi-
cantly decreased the Fas mRNA level in both basic and
ADR treatment conditions, while it had no significant ef-
fects on Survivin mRNA level. Western blot analysis
confirmed that GPI decreased Fas protein level in RA-
FLS in both basic and ADR treatment conditions, while
it had no significant effects on Survivin protein level. In
addition, GPI decreased ADR-induced cleavage of
Caspase-3 in RA-FLS (Figure 4B). Taken together, these
results indicated that the mechanism of GPI-attenuated
apoptosis of FLS is associated with the inhibition of the
Caspase pathway mediated by Fas.
Glucose 6-phosphate isomerase modulates the secretion
of cytokines by fibroblast-like synoviocytes
Finally, we investigated the effect of GPI on the secretion
of cytokines by FLS isolated from RA or OA patients.
ELISA assay showed that the addition of GPI or the trans-
fection of GPI expression vector increased the secretion of
TNF-α and IL-1β by RA and OA FLS, while siRNA-
mediated knockdown of GPI decreased the secretion of
Figure 2 (See legend on next page.)
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Figure 2 GPI promotes the proliferation of FLS isolated from RA or OA patients. A, FLS were transfected with expression plasmids and siRNAs. After
72 hours, the expression of GPI and GP78 was evaluated by Western blot analysis. B, The growth curve of FLS after GPI overexpression and knockdown
(top). The growth curve of FLS after GP78 overexpression and knockdown (bottom). Cell proliferation capacity was determined by MTT assay every
24 hours. A(a) NC-vector versus GPI/gp78-vector, A: P <0.01, a: P <0.05; B(b) si-NC versus si-GPI/gp78, B: P <0.01, b: P <0.05. P values were determined by
Wilcoxon signed-rank test. C, The proliferation of FLS after treatment with GPI (1, 10 μg/ml) for 48 hours. D, The proliferation of FLS after treatment with
anti-GPI Ab (1, 10 μg/ml) for 48 hours. Friedman’s M test and SNK-q test were used for statistics. (N = number of individuals, R = number of replicates;
GPI, glucose 6-phosphate isomerase; gp78, glycoprotein 78;RA, rheumatoid arthritis; OA, osteoarthritis; FLS, fibroblast-like synoviocytes; NC, negative
control; OD, optical density).
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TGF-β and IL-6 by RA and OA FLS did not show any dif-
ference after GPI overexpression or knockdown (Figure 5).
Collectively, these results suggest that GPI modulates the
secretion of TNF-α and IL-1β by FLS.
Discussion
It is generally accepted that GPI is closely associated
with RA [22,23]. In our previous clinical study, we found
that GPI could be a clinical marker for the diagnosis and
therapy of RA [20]. However, the mechanism by which
GPI contributes to the initiation and progression in RA
remains elusive.Figure 3 GPI regulates cell cycle progression of FLS. A, Flow cytometry of the
(left) and the percentages of the indicated cell subsets (right). B, Western blot a
C, Western blot analysis of the levels of GP78 in RA-FLS after GPI overexpression
by Co-IP analysis (right). D, Western blot analysis of the levels of P-ERK, ERK and
a loading control. P values were determined by Wilcoxon signed-rank test (GPI,
arthritis; OA, osteoarthritis; FLS, fibroblast-like synoviocytes; NC, negative control;GPI has been shown to regulate the proliferation and
survival of tumor cells and prevent stress-induced apop-
tosis and oxidative stress-induced cellular senescence in
tumor cells [24-27]. In this study, we found that GPI is
abundant in FLS isolated from patients with RA. To our
knowledge, we demonstrate for the first time that GPI is
also an autocrine factor of FLS. In addition, our results
show that GPI significantly promoted FLS proliferation via
enhancing G1-S transition due to activated ERK-Cyclin
D1 signaling, and inhibited the apoptosis of FLS and aug-
mented the secretion of pro-inflammatory cytokines by
FLS. FLS are key players in the physiopathology of RA
through the local secretion of pro-inflammatory cytokines,cell cycle of RA-FLS after GPI overexpression and knockdown for 48 hours
nalysis of the levels of GP78 in RA-FLS after GPI knockdown for 48 hours.
for 48 hours (left). The interaction between GPI and GP78 was determined
Cyclin D1 in lysates of RA-FLS after GPI overexpression. β-actin was used as
glucose 6-phosphate isomerase; gp78, glycoprotein 78;RA, rheumatoid
ERK, extracellular regulated protein kinases).
Figure 4 (See legend on next page.)
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Figure 4 GPI inhibits the apoptosis of FLS isolated from RA or OA patients. A, FLS were transfected with GPI expression plasmid (top left) and
siRNAs (top right), and 24 hours later were incubated in the absence or presence of 1 μg/ml of ADR for 48 hours. Cell apoptosis was detected
by flow cytometry. Quantitative RT-PCR analysis of Fas, Survivin and Caspase-3 mRNA levels in RA-FLS after GPI overexpression and knockdown
(bottom left). Western blot analysis of Fas, Survivin, Caspase-3 and Cleaved-Caspase-3 levels in RA-FLS after GPI overexpression and knockdown
(bottom right). Friedman’s M test and SNK-q test were used for statistical analysis. B, FLS were pretreated with GPI, and 24 hours later were
incubated in the absence or presence of 1 μg/ml of ADR for 48 hours. Cell apoptosis was detected by flow cytometry (left). Quantitative RT-PCR
analysis of Fas, Survivin and Caspase-3 mRNA levels in RA-FLS after GPI or/and ADR treatment (right). Western blot analysis of Fas, Survivin,
Caspase-3 and Cleaved-Caspase-3 levels in RA-FLS after GPI or/and ADR treatment (right). Friedman’s M test and SNK-q test were used for
statistical analysis. C, FLS were pretreated with GPI antibody, and 24 hours later were incubated in the absence or presence of 1 μg/ml of ADR for
48 hours. Cell apoptosis was detected by flow cytometry. Friedman’s M test and SNK-q test were used for statistical analysis. (N = number of
individuals, R = number of replicates, **P <0.01, *P <0.05).
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grade components of extracellular matrix and destroy the
joint structure [28]. Considering that the synovial tissue of
RA is mainly composed of FLS, these effects of GPI would
account for the pathogenicity of GPI in RA.
Several hypotheses have been proposed to explain ele-
vated GPI antigen in the serum and SF of RA patients.
The hypoxic microenvironment was considered to be one
of the major factors contributing to GPI overexpression.
Hypoxia enhances the expression of GPI in various cancer
cells, including human pancreatic cancer cells and breast
carcinoma cells, accompanied by increased motility of
cancer cells [29-32]. Thus it is proposed that GPI may be
upregulated due to hypoxia in the rheumatoid joint in RA
[33]. Immunohistochemistry analysis demonstrated that
distinct cells at the synovial surface lining of inflamed RA
but not OA joints contained a high concentration of GPI
[19]. However, there is still no direct evidence that syn-
ovial fibroblasts are capable of secreting GPI. In this study,
we demonstrated that RA-FLS, especially isolated fromFigure 5 GPI modulates the secretion of TNF-α, IL-1β, TGF-β and IL-6 in FL
GPI expression plasmids and siRNAs or treated with GPI at 1 μg/ml for 72 h
(A and B), IL-1β (C and D), TGF-β (E and F) and IL-6 (G and H) levels usin
determined by Wilcoxon signed-rank test. (N = number of individuals, R = nGPI (+) RA patients, overexpressed and secreted GPI pro-
tein. Previous studies have suggested that abnormally ele-
vated GPI in the SF of RA patients may come from T cells
and the infiltrating inflammatory cells in the synovium
[9,20]. In addition, the possibility that the diffusion of GPI
from plasma into SF cannot be excluded. However, our re-
sults show that autocrine GPI in FLS contributes to the el-
evated level of GPI antigen in SF.
Since GPI is an autocrine factor of FLS, we further in-
vestigated how GPI contributes to the pathogenesis of RA.
GPI is the second enzyme in the glycolytic pathway and
catalyzes the interconversion of glucose 6-phosphate and
fructose 6-phosphate during glycolysis and gluconeogene-
sis. It is highly conserved in bacteria and eukaryotes [34].
Meanwhile, GPI has been found to function both as a
cytokine and as a growth factor, to regulate cell migration,
proliferation, apoptosis and cellular senescence. The levels
of GPI and its cell surface receptor gp78 are associated
with the pathologic stage, grade and prognosis of tumors
[35-37]. Suppression of GPI led to a contact-dependentS isolated from RA or OA patients. RA or OA FLS were transfected with
ours and the supernatants were collected for the analysis of TNF-α
g ELISA. Data were shown as mean ± SD (N = 8, R = 3). P values were
umber of replicates).
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to form tumor mass [25,38]. In this study, we found that
both endogenous GPI and exogenously added GPI pro-
moted FLS proliferation, while suppression of GPI and
gp78 led to the inhibition of cell growth. Moreover, GPI
antibody decreased FLS proliferation in a concentration-
dependent manner. To better investigate the effect of GPI
on FLS proliferation, we assessed cell cycle progression,
and found that G1-S transition was blocked after GPI
knockdown. Taken together, our results suggest that GPI
promotes cell cycle progression and proliferation of FLS.
GPI stimulates cell motility and growth via a receptor-
mediated signaling pathway involving receptor phosphor-
ylation (a pertussis toxin-sensitive G-protein), inositol
phosphate production, protein kinase C activation and en-
hanced production of a metabolite of arachidonic acid (12
(S)-hydroxyeicosatetraenoic acid cells) [39]. Our data indi-
cate that gp78 expression was upregulated by GPI and
there was a direct interaction between GPI and GP78.
Moreover, we found that the upregulation of GPI mark-
edly activated ERK signaling and increase the expression
of Cyclin D1. ERK protein is involved in several regulatory
pathways that regulate cell proliferation and survival [40].
Cyclin D1/CDK4/CDK6 is a central mediator in the
transition from G1 to S phase. CDK4 and CDK6 form
complexes with D-type Cyclins (D1, D2 and D3) and be-
come active through the phosphorylation by CDK7/
Cyclin H/MATer1 (CDK activating kinase; CAK) [41].
Cyclin D1 expression can be regulated positively by
mitogen-activated protein kinases (MAPKs) pathway
[42]. gp78 is a G-protein coupled receptor (GPCR) that
can active ERK cascade reaction. Collectively, we hy-
pothesized that GPI stimulates cell cycle progression of
FLS via a receptor-mediated signaling pathway thatFigure 6 Schematic model for the role of GPI in the regulation of RA-FLS p
Fas, factor-associated suicide; FasL, factor-associated suicide ligand; FLS, fibr
glycoprotein 78; PKC, protein kinase C.involves gp78 overexpression, GPCR-ERK signaling
activation and Cyclin D1 upregulation (Figure 6).
The overgrowth of FLS in RA is also likely due to an
imbalance between cell proliferation, survival and death.
In this study, we proved that GPI could inhibit the apop-
tosis of FLS, which may promote their survival and par-
ticipation in the pathogenic process. Apoptosis is tightly
regulated by anti- or pro-apoptotic molecules. The Fas/
Caspase signaling pathway is one of the most critical
pathways of apoptosis [43]. In the present study, we
showed that endogenous GPI significantly inhibited the
expression of Fas and the cleavage of Caspase-3, and
promoted the expression of Survivin in FLS. Survivin is an
important inhibitor of apoptosis that is undetectable in
terminally differentiated adult tissues, but is overexpressed
in cancer [44]. Survivin forms complexes, leading to the
release of p21/wafl/cipl for Caspase inactivation [45,46].
Therefore, these results demonstrate that GPI-regulated
apoptosis may be due to the Fas/Caspase and Survivin-
dependent signaling pathway, and further show that GPI
may play an important role in the promotion of rheuma-
toid synovial hyperplasia via the inhibition of FLS apop-
tosis. However, the expression of Survivin did not change
in FLS treated by exogenously added GPI. Further investi-
gation is necessary to elucidate the different effects of en-
dogenous and exogenous GPI on Survivin expression.
It has previously been shown that the level of C1q/
GPI-containing immune complexes (C1q/GPI-CIC) in
the SF of RA patients was significantly higher than that
of the non-RA group, but anti-GPI antibodies did not
exhibit a significant difference [20]. Furthermore, the
transfer of purified GPI-specific autoantibodies from K/
BxN mice was able to induce arthritis in DBA/1 mice
with features similar (but not identical) to those ofroliferation and apoptosis. ERK, extracellular signal-regulated kinase;
oblast-like synoviocytes; GPI, glucose 6-phosphate isomerase; gp78,
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C3 was found on the articular cartilage surface [22].
These studies indicated that GPI and anti-GPI antibodies
might activate the complement pathway and induce
arthritis. In our in vitro cell study, monoclonal anti-GPI
antibody blocked extracellular GPI, leading to the de-
creased growth and increased apoptosis of FLS. These data
showed that anti-GPI antibody played a dual role in GPI-
mediated arthritis. Monoclonal anti-GPI antibody could
block receptor-mediated signal and induce the apoptosis
of FLS. On the other hand, anti-GPI antibody may play a
positive role in the progression of arthritis.
Cytokines are known to play key roles as the media-
tors of RA progression. In particular, TNF-α and IL-1β
act at the upstream of cytokine cascade to induce an ex-
cessive inflammatory reaction in vivo [47]. TNF-α ap-
pears to play important role in triggering events leading
to inflammation both locally and systemically, whereas
IL-1β is involved in cartilage and bone destruction [48].
In the present study we demonstrated that GPI pro-
moted the secretion of TNF-α and IL-1β by FLS isolated
from RA and OA. This further expands the importance
of the pathophysiologic role of GPI in RA.
Conclusions
Taken together, our findings demonstrate that GPI plays
a potential pathophysiologic role in RA through the pro-
motion of proliferation via a receptor-mediated signaling
pathway, the stimulation of the secretion of inflamma-
tory cytokines and the suppression of FLS apoptosis.
Moreover, the elevated expression of GPI and the auto-
crine secretion of GPI by FLS are important aspects of
RA pathology. These data strongly suggest that GPI is a
promising therapeutic target for RA.
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